The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.
 
Ulka N. Vaishampayan
Consulting or Advisory Role - Advanced Accelerator Applications; Alkermes; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Helsinn Therapeutics; Merck Serono; Pfizer
Speakers' Bureau - Bayer; Exelixis; Pfizer
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Merck KGaA
 
Catherine Tangen
No Relationships to Disclose
 
Abhishek Tripathi
Consulting or Advisory Role - EMD Serono; Exelixis; Foundation Medicine; Genzyme; Pfizer
Research Funding - Aravive (Inst); Bayer (Inst); Bayer (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Exact Sciences (Inst); Pfizer (Inst); WindMIL (Inst)
 
Brian M. Shuch
Honoraria - BMS; peloton therapeutics
Consulting or Advisory Role - Bristol-Myers Squibb; Peleton; Pfizer
 
Sumanta K. Pal
Consulting or Advisory Role - F. Hoffmann LaRoche; F. Hoffmann LaRoche; Roche
Research Funding - Eisai (Inst); Exelixis (Inst); Genentech (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Genentech; Seagen
 
Pedro C. Barata
Consulting or Advisory Role - Bayer; BMS; Caris Life Sciences; Clovis Oncology (Inst); Dendreon (Inst); Eisai; EMD Serono; Pfizer
Research Funding - Blue Earth Diagnostics (Inst)
 
Alan Tan
Stock and Other Ownership Interests - Adaptimmune; Aprea AB; Bluebird Bio; crispr therapeutics; Editas Medicine; FATE Therapeutics; Geron; Iovance Biotherapeutics; Jounce Therapeutics; MEI Pharma; Myovant Sciences; Nektar; Sangamo Therapeutics
Honoraria - AstraZeneca; Bristol Myers Squibb Foundation; Verastem
Consulting or Advisory Role - Exelixis; Foundation Medicine
Speakers' Bureau - AstraZeneca; bristol myers squibb; verastem
 
Peggy Zuckerman
No Relationships to Disclose
 
Edward Mayerson
No Relationships to Disclose
 
Primo "Lucky" N. Lara
Consulting or Advisory Role - Calithera Biosciences (Inst); Janssen
Research Funding - Incyte (Inst); Janssen Biotech (Inst); Merck (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst)
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Merck; Novartis; Pfizer; UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Caris Life Sciences; Clovis Oncology; Corvus Pharmaceuticals; Eisai; Genentech/Roche; Janssen Oncology; Merck; Modra Pharmaceuticals; Myovant Sciences; on quality; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Myovant Sciences; Sanofi; Seattle Genetics/Astellas
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; Sanofi/Aventis; US Oncology
 
Hyung Lae Kim
Research Funding - GenomeDx
Patents, Royalties, Other Intellectual Property - I am an inventor of a prognostic biomarker signature and immunotherapies.
 
Ian Murchie Thompson
Consulting or Advisory Role - Magforce; Profound Medical
Research Funding - MagForce
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme